Cyclin D1 in breast cancer pathogenesis

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4215-4224

  Arnold, Andrew ^a   Papanikolaou, Alexandros ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; GEFITINIB; IMATINIB; TRASTUZUMAB; ONCOPROTEIN;

BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; DNA POLYMORPHISM; DRUG TARGETING; GENE ACTIVATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE STRUCTURE; HUMAN; NONHUMAN; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; BREAST TUMOR; FEMALE; GENETICS; METABOLISM;

BREAST NEOPLASMS; CYCLIN D1; FEMALE; HUMANS; ONCOGENE PROTEINS;

EID: 23044508946     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.064     Document Type: Review

References (103)

1. Tomlinson I, Bodmer W: Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog. Nat Med 5:11-12, 1999
2. Devilee P, Cleton-Jansen AM, Cornelisse CJ: Ever since Knudson. Trends Genet 17:569-573, 2001
3. Wang TL, Rago C, Silliman N, et al: Prevalence of somatic alterations in the colorectal cancer cell genome. Proc Natl Acad Sci U S A 99:3076-3080, 2002
4. Haber D, Harlow E: Tumour-suppressor genes: Evolving definitions in the genomic age. Nat Genet 16:320-322, 1997
5. Motokura T, Bloom T, Kim HG, et al: A novel cyclin encoded by a bcl1-linked candidate oncogene. Nature 350:512-515, 1991
6. Xiong Y, Connolly T, Futcher B, et al: Human D-type cyclin. Cell 65:691-699, 1991
7. Matsushime H, Roussel MF, Ashmun RA, et al: Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. Cell 65:701-713, 1991
8. Arnold A, Kim HG, Gaz RD, et al: Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma. J Clin Invest 83:2034-2040, 1989
9. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
10. Bernards R: CDK-independent activities of D type cyclins. Biochim Biochim Biophys Acta 1424:M17-M22, 1999
11. Lamb J, Ramaswamy S, Ford HL, et al: A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell 114:323-334, 2003
12. Rosenberg CL, Wong E, Petty EM, et al: PRAD1, a candidate BCL1 oncogene: Mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 88:9638-9642, 1991
13. Williams ME, Swerdlow SH, Rosenberg CL, et al: Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia 7:241-245, 1993
14. Komatsu H, Iida S, Yamamoto K, et al: A variant chromosome translocation at 11q13 identifying PRAD1/cyclin D1 as the BCL-1 gene. Blood 84:1226-1231, 1994
15. Swerdlow SH, Williams ME: From centrocytic to mantle cell lymphoma: A clinicopathologic and molecular review of 3 decades. Hum Pathol 33:7-20, 2002
16. Bergsagel PL, Kuehl WM: Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 194:96-104, 2003
17. Courjal F, Cuny M, Simony-Lafontaine J, et al: Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: Definition of phenotypic groups. Cancer Res 57:4360-4367, 1997
18. Schuuring E: The involvement of the chromosome 11q13 region in human malignancies: Cyclin D1 and EMS1 are two new candidate oncogenes-a review. Gene 159:83-96, 1995
19. Hughes-Davies L, Huntsman D, Ruas M, et al: EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523-535, 2003
20. Ormandy CJ, Musgrove EA, Hui R, et al: Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 78:323-335, 2003
21. Lammie GA, Fantl V, Smith R, et al: D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 6:439-444, 1991
22. Gillett C, Fantl V, Smith R, et al: Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 54:1812-1817, 1994
23. Bartkova J, Lukas J, Muller H, et al: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361, 1994
24. Jiang W, Zhang YJ, Kahn SM, et al: Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci U S A 90:9026-9030, 1993
25. Zukerberg LR, Yang WI, Gadd M, et al: Cyclin D1 (PRAD1) protein expression in breast cancer: Approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol 8:560-567, 1995
26. Bieche I, Olivi M, Nogues C, et al: Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays. Br J Cancer 86:580-586, 2002
27. Wang TC, Cardiff RD, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671, 1994
28. Barnes DM, Gillett CE: Cyclin D1 in breast cancer. Breast Cancer Res Treat 52:1-15, 1998
29. Gaffey MJ, Iezzoni JC, Meredith SD, et al: Cyclin D1 (PRAD1, CCND1) and glutathione-S-transferase pi gene expression in head and neck squamous cell carcinoma. Hum Pathol 26: 1221-1226, 1995
30. Callender T, el-Naggar AK, Lee MS, et al: PRAD-1 (CCND1)/cyclin D1 oncogens amplification in primary head and neck squamous cell carcinoma. Cancer 74:152-158, 1994
31. Arnold A: The cyclin D1/PRAD1 oncogene in human neoplasia. J Investig Med 43:543-549, 1995
32. Bortner DM, Rosenberg MP: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E. Mol Cell Biol 17:453-459, 1997
33. Sinn E, Muller W, Pattengale P, et al: Coexpression of MMTV/v-Ha-ras and MMTV/ c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo. Cell 49:465-475, 1987
34. Courjal F, Louason G, Speiser P, et al: Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247-253, 1996
35. Miyakis S, Sourvinos G, Spandidos DA: Differential expression and mutation of the ras family genes in human breast cancer. Biochem Biophys Res Commun 251:609-612, 1998
36. Hosokawa Y, Arnold A: Mechanism of cyclin D1 (CCND1, PRAD1) overexpression in human cancer cells: Analysis of allele-specific expression. Genes Chromosomes Cancer 22:66-71, 1998
37. Steeg PS, Zhou Q: Cyclins and breast cancer. Breast Cancer Res Treat 52:17-28, 1998
38. Oyama T, Kashiwabara K, Yoshimoto K, et al: Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 58:2876-2880, 1998
39. Lebwohl DE, Muise-Helmericks R, Sepp-Lorenzino L, et al: A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line. Oncogene 9:1925-1929, 1994
40. Albanese C, Johnson J, Watanabe G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270:23589-23597, 1995
41. Albanese C, D'Amico M, Reutens AT, et al: Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 274:34186-34195, 1999
42. Albanese C, Wu K, D'Amico M, et al: IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 14:585-599, 2003
43. Mulloy R, Salinas S, Philips A, et al: Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22:5387-5398, 2003
44. Coqueret O: Linking cyclins to transcriptional control. Gene 299:35-55, 2002
45. Weinstat-Saslow D, Merino MJ, Manrow RE, et al: Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat Med 1:1257-1260, 1995
46. Alle KM, Henshall SM, Field AS, et al: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4:847-854, 1998
47. Rennstam K, Baldetorp B, Kytola S, et al: Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 61:1214-1219, 2001
48. Motokura T, Arnold A: PRAD1/cyclin D1 proto-oncogene: Genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 7:89-95, 1993
49. Betticher DC, Thatcher N, Altermatt HJ, et al: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 11:1005-1011, 1995
50. Hosokawa Y, Tu T, Tahara H, et al: Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett 93:165-170, 1995
51. Hosokawa Y, Gadd M, Smith AP, et al: Cyclin D1 (PRAD1) alternative transcript b: Full-length cDNA cloning and expression in breast cancers. Cancer Lett 113:123-130, 1997
52. Solomon DA, Wang Y, Fox SR, et al: Cyclin D1 splice variants: Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278:30339-30347, 2003
53. Diehl JA, Sherr CJ: A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17:7362-7374, 1997
54. Alt JR, Cleveland JL, Hannink M, et al: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14:3102-3114, 2000
55. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, et al: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22: 6115-6118, 2003
56. Lu F, Gladden AB, Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63:7056-7061, 2003
57. Hosokawa Y, Joh T, Maeda Y, et al: Cyclin D1/PRAD1/BCL-1 alternative transcript [B] protein product in B-lymphoid malignancies with t(11;14)(q13;q32) translocation. Int J Cancer 81: 616-619, 1999
58. Howe D, Lynas C: The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 86:563-569, 2001
59. Krippl P, Langsenlehner U, Renner W, et al: The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat 82:165-168, 2003
60. Grieu F, Malaney S, Ward R, et al: Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res 23:4257-4259, 2003
61. Sherr CJ, Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999
62. Zhou P, Jiang W, Weghorst CM, et al: Overexpression of cyclin D1 enhances gene amplification. Cancer Res 56:36-39, 1996
63. Lung JC, Chu JS, Yu JC, et al: Aberrant expression of cell-cycle regulator cyclin D1 in breast cancer is related to chromosomal genomic instability. Genes Chromosomes Cancer 34:276-284, 2002
64. Pagano M, Theodoras AM, Tam SW, et al: Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev 8:1627-1639, 1994
65. Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:605-514, 1992
66. Kranenburg O, van der Eb AJ, Zantema A: Cyclin D1 is an essential mediator of apoptotic neuronal cell death. Embo J 15:46-54, 1996
67. Coco Martin JM, Balkenende A, Verschoor T, et al: Cyclin D1 Overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 59:1134-1140, 1999
68. Sweeney KJ, Swarbrick A, Sutherland RL, et al: Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878, 1998
69. Hirai H, Sherr CJ: Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 16:6457-6467, 1996
70. Inoue K, Sherr CJ: Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 18:1590-1600, 1998
71. Horstmann S, Ferrari S, Klempnauer KH: Regulation of B-Myb activity by cyclin D1. Oncogene 19:298-306, 2000
72. Hinds PW, Dowdy SF, Eaton EN, et al: Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci U S A 91:709-713, 1994
73. Zwicker J, Brusselbach S, Jooss KU, et al: Functional domains in cyclin D1: pRb-kinase activity is not essential for transformation. Oncogene 18:19-25, 1999
74. Petre CE, Wetherill YB, Danielsen M, et al: Cyclin D1: Mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 277:2207-2215, 2002
75. Wang C, Pattabiraman N, Zhou JN, et al: Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and trans-activation. Mol Cell Biol 23:6159-6173, 2003
76. Zwijsen RM, Wientjens E, Klompmaker R, et al: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88:405-415, 1997
77. Neuman E, Ladha MH, Lin N, et al: Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4. Mol Cell Biol 17:5338-5347, 1997
78. Buckley MF, Sweeney KJ, Hamilton JA, et al: Expression and amplification of cyclin genes in human breast cancer. Oncogene 8:2127-2133, 1993
79. Gillett CE, Lee AH, Millis RR, et al: Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol 184:396-400, 1998
80. Musgrove EA, Hamilton JA, Lee CS, et al: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993
81. Planas-Silva MD, Weinberg RA: Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 17:4059-4069, 1997
82. Altucci L, Addeo R, Cicatiello L, et al: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12:2315-2324, 1996
83. Zwijsen RM, Buckle RS, Hijmans EM, et al: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12:3488-3498, 1998
84. McMahon C, Suthiphongchai T, DiRenzo J, et al: P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci U S A 96:5382-5387, 1999
85. Sicinski P, Donaher JL, Parker SB, et al: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630, 1995
86. Fantl V, Stamp G, Andrews A, et al: Mice lacking cyclin 01 are small and show defects in eye and mammary gland development. Genes Dev 9:2364-2372, 1995
87. Yu Q, Geng Y, Sicinski P: Specific protection against breast cancers by cyclin D1 ablation. Nature 411:1017-1021, 2001
88. Geng Y, Whoriskey W, Park MY, et al: Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97:767-777, 1999
89. Bowe DB, Kenney NJ, Adereth Y, et al: Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 21:291-298, 2002
90. Keyomarsi K, Tucker SL, Buchholz TA, et al: Cyclin E and survival in patients with breast cancer. N Engl J Med 347:1566-1575, 2002
91. Borg A, Sigurdsson H, Clark GM, et al: Association of INT2/HST1 coamplification in primary breast cancer with hormone-dependent phenotype and poor prognosis. Br J Cancer 63:136-142, 1991
92. Esteva FJ, Hortobagyi GN: Prognostic molecular markers in early breast cancer. Breast Cancer Res 6:109-118, 2004
93. Senderowicz AM: Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene 19:6600-6606, 2000
94. Hsiang CH, Straus DS: Cyclopentenone causes cell cycle arrest and represses cyclin D1 promoter activity in MCF-7 breast cancer cells. Oncogene 21:2212-2226, 2002
95. Sawatsri S, Samid D, Malkapuram S, et al: Inhibition of estrogen-dependent breast cell responses with phenylacetate. Int J Cancer 93: 687-692, 2001
96. Sauter ER, Nesbit M, Litwin S, et al: Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res 59:4876-4881, 1999
97. Arber N, Doki Y, Han EK, et al: Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57:1569-1574, 1997
98. Kornmann M, Arber N, Korc M: Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 101: 344-352, 1998
99. Borthakur G, Cortes JE: Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79:411-419, 2004
100. Nahta R, Esteva FJ: HER-2-targeted therapy: Lessons learned and future directions. Clin Cancer Res 9:5078-5084, 2003
101. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
102. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
103. Weinstein IB: Cancer. Addiction to oncogenes: The Achilles heal of cancer. Science 297:63-64, 2002